Bioceres Crop Solutions Corp. · NASDAQ:BIOX
Bioceres Crop Solutions — FY2020 Earnings Presentation
20 slides from Bioceres Crop Solutions's earnings presentation, Sep 10, 2020

Slide 1: Fourth Quarter and Fiscal Year 2020 Earnings Call Presentation
Fourth Quarter and Fiscal Year 2020 Earnings Call Presentation September 10, 2020

Slide 2: Disclaimer And Forward-Looking Statement
Disclaimer And Forward-Looking Statement This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial instruments of the Company or

Slide 3: Executing on Growth Strategy while Substantially Strengthening Balance Sheet
Executing on Growth Strategy while Substantially Strengthening Balance Sheet Continued international expansion supported by leading position in Argentina, plus a more profitable mix - 4Q20 Comparable revenues +46% YoY and +17% to $ 174M in FY20 - 4Q20 Adjusted EBITDA +67% and +13% to $ 46M in FY20

Slide 4: Update on EcoSoy
Update on EcoSoy® Key Highlights Geographical Distribution for FY21 FY20 hectares fully harvested HB4 4519 RG Repositioned >50% of materials met seed quality and varieties to HB4 5519 performance metrics HB4 hot zones Varieties that met HB4 4619 RG STS expectations and are continued at full scal

Slide 5: Update on EcoWheat
Update on EcoWheat® Key Highlights EcoWheat in the Media ~7,000 hectares planted out of the 12,000 10 notes that include reserved testimonies of producers, opinion of academics, politicians and decision- Severe drought conditions prevented some makers of our grower-partners from initiating multi

Slide 6: Successful Completion of Warrant Tender Offer
Succesful Completion of Warrant Tender Offer Company removed all its 24.2M outstanding Warrants for either 0.12 ordinary shares or $0.45 in cash per warrant Transaction executed in 29 days (from announcement to redemption of non-tendered warrants) Removed overhang of Bioceres’ outstanding warr

Slide 7: BIOX Warrant Tender Offer Results
BIOX Warrant Tender Offer Results 24.2M Warrants removed 90% 10% 21.9M 2.3M Warrants validily tendered Warrants redeemed for $0.405 in cash 21.7M 0.2M 2.6M1 $ 0.1M Exchange Shares in Cash in exchange for exchange for Warrants tendered Warrants (.12) tendered ($.45) $ 1.0M 11.7M shares incorporated i

Slide 8: Robust Top Line Growth Driven by Solid Performance Across All Segments
Robust Top Line Growth Driven by Solid Performance Across All Segments Comparable Segment Revenues ($ in millions) YoY Revenues largely linked to US dollar, except in Brazil 4Q20 +46%, driven by strong sales of adjuvants, as well as bio-fungicides, inoculants and seed treatment packs across regi

Slide 9: Crop Protection Highlights
Crop Protection Highlights Comparable Segment Revenues ($ in millions) YoY 4Q20 +29%, led by sustained expansion in Brazil’s adjuvant market, supported by normalized demand in Argentina. Continued growth in environmentally friendly bio-fungicides FY20 +13%, on consistent execution of adjuvant gr

Slide 10: Seed & Integrated Products Highlights
Seed & Integrated Products Highlights Comparable Segment Revenues ($ in millions) YoY 4Q20 +175%, driven by seed treatment pack sales1 at South African subsidiary and sustained recovery of packs in Argentina, following highly successful pre-season summer crop sales campaign there FY20 +32%, high

Slide 11: Crop Nutrition Highlights
Crop Nutrition Highlights Comparable Segment Revenues ($ in millions) YoY 4Q20 +46%, strong demand for micro-beaded fertilizer ahead of a winter crops planting season in Argentina, supported by continued penetration of Brazil’s inoculants B2B market FY20 +18%, on greater demand for micro-beaded

Slide 12: Comparable Consolidated Gross Profit and Margin
Comparable Consolidated Gross Profit and Margin Gross Profit ($ in millions) & Margin YoY 4Q20 Gross Profit +51%, with margin expanding 138 bps to 48.7%, mainly driven by greater proportion of higher margin S&IP sales within the revenue mix, enhanced by favorable FX and inflation dynamics FY20 G

Slide 13: Adjusted EBITDA Driven by Top Line Performance and Operating Leverage
Adjusted EBITDA Driven by Top Line Performance and Operating Leverage 4Q20 EBITDA Bridge ($ in millions) Adj. EBITDA 17.6% 30.5% Margin 14.7 16 4.5 0.6 14 0.5 12 2.0 10 8.8 0.6 8 1.3 6 4 2 0 Adjusted EBITDA Gross profit Crop Gross profit Seed Gross profit Crop Operating JV's Other income or Adjusted

Slide 14: Strong Balance Sheet: Increased Liquidity and Improved Debt Profile
Strong Balance Sheet: Increased Liquidity and Improved Debt Profile Raised a total of $65 M in FY20 including $15 M in public corporate bonds in 4Q20 due Dec’21 Improved debt maturity profile: long-term debt at 57% of total debt, up from 37% in 4Q19 Enhanced financial liquidity: cash & equival

Slide 15: Higher Cash Generation via Lower Financing Costs
Higher Cash Generation via Lower Financing Costs Lowered total net interest expenses and financial commissions by 56% in 4Q20, by reducing average cost of debt and replacing inefficient external working capital sources, resulting in 25% drop in FY20 Strong asset base remains in place to support

Slide 16: Looking ahead
Looking ahead Accelerating HB4® Program Continue consolidating our HB4 soybean breeding program with our existing licensees and other breeding partners, to expand on Bioceres’ genetics offering Accelerate international HB4 deployment plans, particularly in the United States and Brazil Strong foc

Slide 17: Exhibits
7’ BIOCERES CROP SOLUTIONS EXHIBITS September 10, 2020

Slide 18: Unaudited Consolidated Statement of Comprehensive Income
Unaudited Consolidated Statement of Comprehensive Income Figures in $ millions Three-month period ended Three-month period ended Fiscal year ended Fiscal year ended 06/30/2020 06/30/2019 06/30/2020 06/30/2019 Total revenue 48.2 49.9 173.1 160.6 Cost of sales (25.3) (28.3) (93.6) (87.0) Gross profit

Slide 19: Unaudited Consolidated Statement of Financial Position
Unaudited Consolidated Statement of Financial Position Figures in $ millions ASSETS 06/30/2020 06/30/2019 LIABILITIES 06/30/2020 06/30/2019 CURRENT ASSETS CURRENT LIABILITIES Cash and cash equivalents 34.9 3.5 Trade and other payables 57.3 40.6 Other financial assets 21.0 4.7 Borrowings 63.6 66.5 Tr

Slide 20: Contact Us
Contact Us Investor Relations Investorrelations@biocerescrops.com (54) 0341 4861100 Investors.biocerescrops.com
Source: Internet Archive copy of s26.q4cdn.com
More decks from Bioceres Crop Solutions Corp.
Q4 2026 Earnings Presentation17 slides · Sep 15, 2026
Q3 2026 Earnings Presentation16 slides · May 12, 2026
Q1 2026 Earnings Presentation13 slides · Nov 13, 2025
Q4 2025 Earnings Presentation16 slides · Sep 9, 2025
Q3 2025 Earnings Presentation18 slides · May 21, 2025
Q2 2025 Earnings Presentation20 slides · Feb 12, 2025